Laura G. Eichorn - 22 Feb 2022 Form 4 Insider Report for Imago BioSciences, Inc.

Role
Chief Operating Officer/Interim CFO
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
Issuer symbol
N/A
Transactions as of
22 Feb 2022
Net transactions value
-$152,653
Form type
4
Filing time
24 Feb 2022, 17:05:59 UTC
Previous filing
15 Feb 2022
Next filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $20,160 +8,000 +3.9% $2.52* 215,737 22 Feb 2022 Direct F1
transaction IMGO Common Stock Sale $163,949 -7,600 -3.5% $21.57 208,137 22 Feb 2022 Direct F1, F2
transaction IMGO Common Stock Sale $8,864 -400 -0.19% $22.16 207,737 22 Feb 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -8,000 -7.3% $0.000000 101,956 22 Feb 2022 Common Stock 8,000 $2.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $21.03 to $21.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $22.07 to $22.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Chief Operating Officer/Interim CFO